Please assess the completion status of the following clinical trial:

Trial Title: A Research Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of DUR-928 in Patients With Alcoholic Hepatitis

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~1. Able to provide written informed consent (either from patient or patient's legally acceptable representative)~2. Male or female patients 21 years of age or older with BMI ≥ 20 to ≤ 40 kg/m2~3. Patients with alcoholic hepatitis defined as:~   1. History of heavy alcohol abuse: \> 40 g/day in females or \> 60 g/day in males for a minimum period of 6 months, AND~  2. Consumed alcohol within 12 weeks of entry into the study, AND~  3. Serum bilirubin \> 3 mg/dL AND AST \> ALT, but less than 300 U/L AND~  4. MELD score between 11-30, inclusive~4. No evidence of active infection as determined by the investigator.~5. Women of child-bearing potential must utilize appropriate birth control throughout the study duration.~6. Male patients must agree to use a medically acceptable method of contraception/birth control throughout the study duration~Exclusion Criteria:~1. Other or concomitant cause(s) of liver disease as a result of:~   1. Autoimmune liver disease~  2. Wilson disease~  3. Vascular liver disease~  4. Drug induced liver disease~2. Co-infection with human immunodeficiency virus (HIV) or Hepatitis B~3. Any active malignancies other than curatively treated skin cancer (basal cell or squamous cell carcinomas)~4. If female, known pregnancy, or has a positive serum pregnancy test, or lactating/breastfeeding~5. Serum creatinine \> 2.5 mg/dL~6. Patients who have had organ transplantation (such as liver, kidney, lung, heart, bone marrow, or stem cell etc.), other than cornea transplant~7. Stage 3 or greater encephalopathy by West Haven criteria

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Part A (Moderate AH) DUR-928 30 mg (Type: EXPERIMENTAL): Lowest dose of 3 dose escalation arms: 30mg, 90 mg and 150 mg
- Part A (Moderate AH) DUR-928 90 mg (Type: EXPERIMENTAL): Middle dose of 3 dose escalation arms: 30mg, 90 mg and 150 mg
- Part A (Moderate AH) DUR-928 150 mg (Type: EXPERIMENTAL): Highest dose of dose escalation arms: 30mg, 90 mg and 150 mg
- Part B (Severe AH) DUR-928 30 mg (Type: EXPERIMENTAL): Lowest dose of dose escalation arms: 30mg, 90 mg and 150 mg
- Part B (Severe AH) DUR-928 90 mg (Type: EXPERIMENTAL): Middle dose of dose escalation arms: 30mg, 90 mg and 150 mg
- Part B (Severe AH) DUR-928 150 mg (Type: EXPERIMENTAL): Highest dose of dose escalation arms: 30mg, 90 mg and 150 mg

Based on this trial design, predict the completion outcome and termination type (if applicable).